Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis  by Iodice, Carmela et al.
Kidney International, Vol. 63 (2003), pp. 2214–2221
Maximal suppression of renin-angiotensin system in
nonproliferative glomerulonephritis
CARMELA IODICE, MARIO M. BALLETTA, ROBERTO MINUTOLO, PAOLO GIANNATTASIO,
STEFANO TUCCILLO, VINCENZO BELLIZZI, MAURIZIO D’AMORA, GIORGIO RINALDI,
GIUSEPPE SIGNORIELLO, GIUSEPPE CONTE, and LUCA DE NICOLA
Department of Nephrology and Department of Biostatistic, School of Medicine, Second University of Naples, Naples, Italy;
Department of Nephrology, School of Medicine, University Federico II of Naples, Naples, Italy; Department of Pathology,
S.M.del P. Incurabili Hospital, Naples, Italy; and Nephrology-Dialysis Unit, Lauria Hospital, Naples, Italy
suppression up to the maximal degree does not improve theMaximal suppression of renin-angiotensin system in nonprolif-
antiproteinuric response and is coupled with a decrement oferative glomerulonephritis.
hemoglobin levels.Background. Elimination of residual proteinuria is the novel
target in renoprotrection; nevertheless, whether a greater sup-
pression of renin-angiotensin system (RAS) effectively improves
the antiproteinuric response in patients with moderate protein-
Proteinuria is an important and independent risk fac-uria remains ill-defined.
tor for disease progression and end-stage renal diseaseMethods. We evaluated the effects of maximizing RAS sup-
pression on quantitative and qualitative proteinuria in ten pa- (ESRD) in nondiabetic chronic nephropathies [1]; pro-
tients with stable nonnephrotic proteinuria (2.55  0.94 g/24 tein filtration is, in fact, associated with protein overabsorp-
hours) due to primary nonproliferative glomerulonephritis
tion by renal tubules that induces inflammatory events(NPGN), and normal values of creatinine clearance (103  17
and, ultimately, damage at the tubulointerstitial levelmL/min). The study was divided in three consecutive phases:
(1) four subsequent 1-month periods of ramipril at the dose [2, 3]. In nonproliferative glomerulonephritis (NPGN),
of 2.5, 5.0, 10, and 20 mg/day; (2) 2 months of ramipril 20 mg/ the contribution of proteinuria to the pathophysiology of
day  irbesartan 300 mg/day; and (3) 2 months of irbesartan progression of renal damage is more prominent than in300 mg/day alone.
proliferative glomerulopathies, where other factors playResults. Maximizing RAS suppression was not coupled with
a role [2]. Identification of the most effective antiprotein-any major effect on renal function and blood pressure; con-
versely, a significant decrement in hemoglobin levels, of 0.8 g/dL uric treatment becomes therefore critical in NPGN.
on average, was observed during up-titration of ramipril dose. In NPGN, the presence of nephrotic syndrome identi-
The 2.5 mg dose of ramipril significantly decreased proteinuria
fies the best candidates to immunosuppressive treatment;by 29%. Similar changes were detected after irbesartan alone
however, this therapeutic intervention allows a complete(28%). The antiproteinuric effect was not improved either
by the higher ramipril doses (30% after the 20 mg dose) or remission of proteinuria in about 50% of cases [4–6]. In
after combined treatment (33%). The reduction of protein- addition, moderate degrees of proteinuria are detected
uria led to amelioration of the markers of tubular damage, as since the beginning of the disease or during relapses intestified by the significant decrement of 1 microglobulin (1m)
a substantial number of patients [4–6]. In these patients,excretion and of the tubular component of proteinuria at so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- with either induced or spontaneous residual proteinuria,
PAGE). treatment remains ill-defined. Conversely, it is important
Conclusion. In nonnephrotic NPGN patients, standard doses to underscore that long-term studies have demonstratedof either ramipril or irbesartan lead to significant reduction of
that, in NPGN, only complete remission of proteinuriaresidual proteinuria and amelioration of the qualitative fea-
ensures excellent renal prognosis [5, 6], while persistencetures suggestive of tubular damage. The enhancement of RAS
of even moderate degrees of proteinuria is still coupled
with progressive decline of renal function and, moreover,
Key words: membranous nephropathy, focal segmental glomeruloscle-
with increased risk for cardiovascular mortality [7, 8].rosis, converting enzyme inhibitor, angiotensin receptor antagonist,
SDS-PAGE, urinary 1m. Indeed, elimination of residual proteinuria is now consid-
ered as the main target in renoprotrection [9, 10]. To this
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to start such a treatment early in the course of disease,
that is, prior to development of chronic renal failure [9–11].
In this regard, we have recently evidenced in a small
group of patients with moderate proteinuria due to pro-
liferative glomerulonephritis (IgA nephropathy) that co-
administration of angiotensin-converting enzyme inhibi-
tor (ACE-I) and angiotensin II (Ang II) AT1 receptor Fig. 1. Study design. Angiotensin-converting enzyme inhibitor (ACE-I)
antagonist (ARA) decreases proteinuria by a greater ex- was ramipril and angiotensin II AT1 receptor (ARA) was irbesartan.
The doses of the two agents were given in doses of mg/day. Basaltent (63%) than the single agents alone (35%) [12, 13].
evaluation was performed at time 0.The rationale for combination therapy is based on the
assumption that ARA would counteract the AT1-medi-
ated effects of Ang II formation by non-ACE enzymes
while ACE-I would additionally increase kinins [14]. the large number of visits and/or excessive distance of
the hospital from their residence.Whether enhancement of RAS suppression allows a ma-
jor antiproteinuric response in NPGN patients with mod-
Study designerate proteinuria is unknown.
In the present work, we studied NPGN patients with This was an open-label study, performed on ambula-
tory basis, designed to compare prospectively the anti-nonnephrotic proteinuria and normal glomerular filtra-
tion rate (GFR). We monitored the antiproteinuric re- proteinuric response to stepwise enhancement of RAS
suppression with the patients’ basal values as their ownsponse during treatment with ramipril at doses progres-
sively increased in a stepwise fashion, from 2.5 up to 20 control. The study lasted 14 months (Fig. 1). Two months
after withdrawal of eventual therapy with ACE-I ormg/day, then after adding irbesartan 300 mg/day to the
maximal dose of ACE-I, and, finally, after irbesartan ARA (run in), patients underwent the clinical and bio-
chemical basal evaluation and started the active treat-alone. The study was aimed at evaluating whether in
these patients the antiproteinuric response to ACE-I is ment protocol constituted by three consecutive phases:
(1) four subsequent 1-month periods of treatment witha dose-related phenomenon and add-on ARA enhances
the antiproteinuric effect of maximized ACE inhibition. ramipril at the dose of 2.5, 5.0, 10, and 20 mg/day; (2)
2 months of ramipril 20 mg/day  irbesartan 300 mg/day;Since, in NPGN, renal prognosis is significantly worsened
by the urinary excretion of proteins of low molecular and (3) 2 months of irbesartan 300 mg/day alone. Two-
month intervals of washout followed each phase. Studyweight [15–17], the so-called tubular proteinuria, we also
evaluated the effect of maximal RAS suppression on the medication was administered twice a day (8:00 a.m. and
8:00 p.m.); in the study days, the morning dose was takenqualitative features of proteinuria.
after data collection at the outpatient clinic (between
8:00 and 9:00 a.m.). All patients were required to main-
METHODS
tain their usual salt intake throughout the period of the
Patients study.
We screened all adult patients followed in the outpa-
Clinical and laboratory procedurestient renal clinic from December 1998 through Decem-
ber 2000 to select those who met the following enrollment Assessment of clinical and laboratory parameters was
performed at baseline, at the end of each month of thecriteria: biopsy-proven primary NPGN, moderate pro-
teinuria (1.0 to 3.5 g/day), and serum albumin levels3.0 first phase, at the end of the subsequent two phases, and
at the end of each of the three washout periods. In addi-g/dL persisting for at least 12 months prior to the study
in the absence of any immunosuppressive treatment and tion, to ensure the safety of the patients, serum creatinine
and potassium, as well as blood pressure, were measurednormal renal function (creatinine clearance70 mL/min).
We excluded patients with evidence of edema, diabetes between the 10th and the 15th day following any change
of medication prescription. We measured at each stepmellitus, renovascular disease, obstructive uropathy, se-
rum potassium 5.5 mmol/L, cancer, chronic treatment proteinuria, urinary levels of1-microglobulin (1m), cre-
atinine, sodium (UNaV). and urea, as well as body weight,with anti-inflammatory drugs, and known or suspected
intolerance to ACE-I or ARA. blood pressure, serum creatinine, potassium, albumin,
hemoglobin, peripheral plasma renin activity (PRA),Ten patients out of the 31 patients were found to be
eligible in the 2-year period of screening and gave their and aldosterone.
Blood pressure was measured in the morning beforeinformed consent to enter onto the study. The remaining
21 eligible patients refused enrollment. The reasons they drug administration by a mercury sphygmomanometer
after 10 minutes’ rest. The first and fifth Korotkoff soundsgave included their fear of the potential side effects of
the high-dose “antihypertensive” therapy or because of were used as systolic and diastolic blood pressure levels.
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The mean of three consecutive measurements taken 2 molecular-weight (LMW) and the very low-molecular-
weight (VLMW) on the basis of the absence or presenceminutes apart in the sitting position was used for statisti-
cal analysis. Mean blood pressure was calculated as the of protein bands with a molecular weight 23 kD, re-
spectively. For the analysis of SDS-PAGE data, we as-sum of one third of systolic and two thirds of diastolic
blood pressure. Blood pressure measurements were re- signed a score to each pattern: VLMW  1, LMW  2,
pure glomerular  3, physiologic  4; indeed, previouspeated after 5 minutes in standing position to detect
eventual orthostatic hypotension. studies have demonstrated significant differences in terms
of tubulointerstitial damage and renal prognosis amongAll the urinary samples were stored and analyzed at
the same time. At each step, proteinuria was measured the four categories, with VLMW being characterized by
the worst and physiologic by the best outcome [15, 16].in two consecutive 24-hour urine collections (the mean
value was recorded and used for statistical analysis) with Serum albumin, serum and urinary levels of creatinine,
urea, sodium, and potassium were measured by an auto-the pyrogallol red-molibdate method; the intra-assay and
interassay coefficients of variation of this method was analyzer (Olympus AU 400, Olympus Italia, Segrate,
Italy). Daily urea excretion was used to calculate proteinless than 2%. The urinary levels of 1m were assessed by
immunonephelometric method on a Coulter Beckman intake as described in a previous paper by our group [18].
Hemoglobin was measured by Coulter counter (Coulternephelometer, using caprine serum antihuman1m (Beck-
man, Fullerton, CA, USA). The intra-assay and inter- Electric, Hialeah, FL, USA). PRA and aldosterone were
measured by a radioimmunoassay (RIA) technique us-assay coefficients of variation of this method was less
than 5%. ing commercial kits (DPC, Los Angeles, CA, USA).
The pattern of urinary proteins was determined at
Statisticsbaseline, and at the end of the three phases (uptitration
of ramipril dose, combined treatment, and irbesartan Results are reported as mean  SD. Analysis of vari-
ance for repeated measures was always applied to com-alone) by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), as previously described pare arms, using pretreatment values as covariates when
appropriate. With only two groups to be compared that[15]. The Mini-Protean II apparatus (Bio-Rad Labora-
tories, Hercules, CA, USA) was used. Urine samples analysis reduces to a paired t test. Focus was on the
following predefined questions: (1) Do the three differ-(the volume ranged from 2 to 19 	L to apply a protein
amount of 3.5 	g) were applied to polyacrylamide gel ent treatments (ACE-I, ARA, ACE-I  ARA) have
any effect on pre-treatment values? (2) Is there a doseslab (85 
 70 
 1 mm, 12% of acrylamide/N,N’-methyl-
ene bis-acrylamide, 30% weight/volume). Electrophore- effect of ACE-I treatment? (3) Is the effect of ACE-I 
ARA greater than that of single agents? Since treatmentssis was programmed to run at 60 volts for stacking and
110 volts for running layer of slabs in discontinuous run- were assigned sequentially and a carryover bias could
possibly confound results, a washout period of 2 monthsning buffer, using the Bio-Rad Power Supply Model 200/
2.0 apparatus (Bio-Rad Laboratories). The gels were was planned among the different treatments; therefore,
similarity of pretreatment conditions was preliminarilystained with Coomassie blue R 250 (which produces blue
protein bands with sensitivity as low as 8 to 28 ng) for 30 tested to exclude a carryover effect. A period effect could
not be tested; indeed, we could not randomize the typeminutes at room temperature; subsequently, they were
distained with an acetic acid/methanol/aqueous solution of treatment because administration of either ACE-I at
high dose or combined treatment without preliminary(1:5:4 volume) to give sufficiently clear background and
fixed between two cellophane papers and dried. The evaluation of the effects of ACE-I at lower doses would
have been unethical in our normotensive patients. Fi-molecular weight of urinary protein bands was assessed
by comparison with standard protein of known molecular nally, to test whether the antiproteinuric effect of treat-
ment was mediated by the blood pressure lowering ef-weight (10 kD Protein Ladder; GIBCO BRL, Uxbridge,
UK), using Ultrascan XL 2222 Densitometer (Pharmacia fect, the pre- and posttreatment values of proteinuria
were analyzed using the respective values of blood pres-LKB Biotechnology AB, Uppsala, Sweden). The SDS-
PAGE patterns are classified according to the presence sure (systolic, diastolic, and mean) as covariates. We also
estimated correlation coefficients between changes inof protein bands of different molecular weights [15, 16].
Specifically, the pattern characterized by the albumin proteinuria and concomitant changes in systolic blood
pressure, diastolic blood pressure and mean blood pres-band alone (68 kD) is considered “physiologic,” while
the presence, beside albumin, of protein bands of molec- sure. Two-tailed significance level was 0.05.
A sample size of ten patients adequately allowed anular weight 68 kD identifies the “pure glomerular”
pattern. A “tubular” pattern is defined by the presence, average power of 89% (range, 80% to 95% depending on
the number of groups compared) to detect a difference inbeside albumin and proteins with molecular weight68,
of protein bands with molecular weight 68 kD; specifi- means across the levels of repeated measures factor
equal to half of the common standard deviation, that is,cally, two tubular patterns can be distinguished: the low-
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Table 1. Clinical and biochemical data at baseline and after increasing ramipril dose [angiotensin-converting enzyme inhibitor (ACE-I)],
ramipril 20 mg/day plus irbesartan 300 mg/day [ACE-I  angiotensin II AT1 receptor (ARA)] and irbesartan 300 mg/day (ARA) in
10 patients with nonproliferative glomerulonephritis (NPGN)
ACE-I mg/day ACE-I  ARA ARA
Baseline 2.5 5.0 10 20 Washout 20  300 Washout 300 Washout
Systolic blood pressure
mm Hga,c,d 1187 10310 10514 10313 1007 1175 9911 11711 10311 1189
Diastolic blood pressure
mm Hga,c,d 754 687 688 698 667 756 647 7611 666 767
Serum K mEq/L 4.50.3 4.50.4 4.60.4 4.60.4 4.50.4 4.50.3 4.50.5 4.60.4 4.50.4 4.40.3
Hemoglobin g/dLa,b,e 14.61.1 14.61.2 14.11.0 14.21.1 13.81.0 14.31.2 13.90.9 14.71.3 14.31.1 14.61.2
PRA ng/mL/houra,b,c,d,e 2.20.8 4.22.3 4.72.1 5.53.2 7.13.4 2.41.1 10.73.8 2.30.7 7.12.4 2.41.5
Aldosterone pg/mLa,b,d,e 8221 8033 7519 6917 4422 7517 3918 7429 6528 7723
Creatinine clearance
mL/min/1.73 m2 10317 10219 10419 10416 10315 10319 10220 10018 10120 10319
UNaV mEq/day 16760 15856 16374 15265 16140 15859 16260 17066 17383 15775
The values are mean  SD. Abbreviations are: PRA, peripheral plasma renin activity; UNaV, urinary sodium excretion.
a P  0.05 for ACE-I vs. pretreatment values; b P  0.05 for dose effect of ACE-I; c P  0.05 for ARA vs. pretreatment value; d P  0.05 for ACE-I  ARA vs.
pretreatment values; e P  0.05 for differences among treatment arms
an effect size of 0.5 at a significance level of 0.05 (nQuery ACE-I versus pretreatment conditions was observed for
systolic blood pressure (P 0.0001), diastolic blood pres-Advisor 1.0, 1995).
sure (P  0.0007), mean blood pressure (P  0.0002),
PRA (P 0.001), aldosterone (P 0.04), and hemoglo-
RESULTS bin (P  0.05).
We studied two females and eight males with a mean ACE-I treatment significantly affected proteinuria
age of 34 years old (range, 21 to 51 years). The histologic (P 0.0005) and1m (P 0.03). At baseline, proteinuria
diagnosis was idiopathic membranous nephropathy (N  averaged 2.55  0.94 g/day (range, 1.1 to 3.2 g/day). The
5) and primary focal segmental glomerulosclerosis (N 5). decrement of proteinuria during ACE-I was equal to
Seven of the patients studied had been previously treated 30% on average, with the lowest dose of ramipril (2.5
mg/day) inducing a 29% reduction.with immunosuppressive therapy (steroids alone or in
combination with cyclophosphamide). At baseline, body
Dose-effect of ACE-Iweight was 69.3  10 kg and serum albumin was 3.8 
A statistically significant effect of the different doses0.6 g/dL; these values did not change throughout the
of ramipril (from 2.5 up to 20 mg/day) was observed fordifferent steps. Similarly, protein intake, that averaged
PRA that increased from 4.2 to 7.1 ng/mL/hour (P 1.14  0.12 g/kg body weight/day at baseline, did not
0.004), aldosterone that decreased from 80 to 44 pg/mLvary subsequently.
(P  0.006), 1m that decreased from 26.0 to 19.2 mg/We did not detect in any patient, at any step, either
day (P  0.04), and hemoglobin that decreased fromacute renal failure (that is, an increment of serum creati-
14.6 to 13.8 g/dL (P  0.003). Conversely, no differencenine 30% versus pretreatment values), or hyperka-
among the different doses of ACE-I was observed forlemia (that is, serum K 5.5 mmol/L). No symptomatic
proteinuria (P  0.94), systolic blood pressure (P hypotensive episodes, dizziness, or fatigue were observed
0.72), diastolic blood pressure (P  0.62), and meanthroughout the study.
blood pressure (P 0.64). The same held true for creati-The main clinical and biochemical features of patients
nine clearance, serum potassium, and UNAV.according to the type of treatment are summarized in
Table 1, with the exception of proteinuria and 1m excre- Effect of ARA treatment
tion that have been reported in Figure 2. No difference was observed for creatinine clearance,
serum potassium, UNAV, aldosterone, and hemoglobin,Carryover effect
while a significant effect of ARA versus pretreatment
No difference was found across the pretreatment val- conditions was observed for Uprot (P  0.003) that de-
ues (baseline and washout periods) of the parameters creased by 28%, 1m (P  0.04), systolic blood pressure
examined, testifying that basal conditions were always (P  0.003), diastolic blood pressure (P  0.01), mean
restored after washout periods. blood pressure (P  0.003), and PRA (P  0.0005).
Effect of ACE-I treatment Effect of combination ACE-I  ARA
No difference was detected for creatinine clearance, A significant effect of combination versus pretreatment
conditions was observed for proteinuria (P  0.0009),serum potassium, and UNaV, while a significant effect of
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Fig. 2. Effect of increasing ramipril dose, com-
bined therapy, and irbesartan alone on proteinuria
and 1microglobulin (1m) in ten patients with
nonproliferative glomerulonephritis (NPGN).
Data are meanSD. aP 0.05 for angiotensin-
converting enzyme inhibitor (ACE-I) vs. pre-
treatment values; bP  0.05 for dose effect of
ACE-I; cP 0.05 for angiotensin II AT1 recep-
tor (ARA) vs. pretreatment values; dP  0.05
for ACE-I  ARA vs. pretreatment values;
eP 0.05 for differences among treatment arms.
Table 2. Pattern of urinary proteins at baseline and after uptitration1m (P  0.03), systolic blood pressure (P  0.002), of ramipril dose [angiotensin-converting enzyme inhibitor (ACE-I)],
diastolic blood pressure (P  0.001), mean blood pres- combined treatment [ACE-I  angiotensin II AT1 receptor (ARA)]
sure (P  0.0006), PRA (P  0.0001), and aldosterone and irbesartan alone (ARA) at sodium dodecylsulfate-
polyacrylamide gel electrophresis (SDS-PAGE) analysis(P  0.003). No difference was detected for creatinine
clearance, serum potassium, and UNaV. Hb level de- ACE-I 
Baseline ACE-I ARA ARAcreased by 0.4 g/dL on average with respect to the wash-
out value; at variance with what observed after adminis- VLMW number 4 1 1 1
LMW number 6 8 8 7tration of ramipril alone, this difference did not reach
GLOM number 0 0 0 1statistical significance because the hemoglobin value at PHYS number 0 1 1 1
the end of washout resulted numerically lower than the Score 1.600.52 2.100.74a 2.100.74a 2.200.79a
basal hemoglobin level. The values are meanSD. Abbreviations are: VLMW, very low-molecular-
weight pattern; LMW, low-molecular-weight pattern; GLOM, glomerular pattern;
PHYS, physiologic pattern. The score assigned at each pattern was as following:Effect of the combination ACE-I  ARA versus
VLMW  1, LMW  2, GLOM  3, PHYS  4.single agents aP  0.05 vs. baseline
A significant difference among the three arms was ob-
served only for PRA (P 0.01), aldosterone (P 0.005),
and hemoglobin (P 0.02). Conversely, no difference was
lar, the pattern was LMW in six and VLMW in fournoted for proteinuria (P  0.94), that decreased by 33%
patients (Table 2). At the end of up-titration of ramiprilin the combination arm, 1m (P  0.33), systolic blood
dose, the pattern changed from VLMW to LMW in threepressure (P  0.46), diastolic blood pressure (P  0.80),
patients, and from LMW to physiologic in one patient.and mean blood pressure (P 0.62). The same held true
No further change was detected in the subsequent stepsfor serum potassium, creatinine clearance, and UNaV.
with the exception of a shift from LMW to pure glomeru-
Relationship between antiproteinuric and blood lar pattern in one patient at the end of the study. The
pressure lowering effect amelioration of pattern was testified by the significant
increase of score.After adjustment by values of blood pressure (systolic,
diastolic, and mean), the mean values of proteinuria did
not significantly vary during ramipril 2.5 mg/day (from DISCUSSION
an unadjusted decrease of 0.8 g/day to values of 0.7 g/day
In NPGN, previous studies have evaluated the antipro-adjusted for systolic, diastolic, and mean blood pres-
teinuric effect of either increasing the dosage of ACE-I/sures). Similar results were obtained when considering
ARA [19–23], or combining the two agents [23, 24]. Inthe higher doses of ramipril, combined treatment, and
all these studies, however, patients were characterizedirbesartan alone. Accordingly, no significant correlation
by nephrotic proteinuria and renal dysfunction, that is,was found between the percentual changes of proteinuria
features that usually indicate prescription of immuno-and systolic, diastolic, and mean blood pressures.
suppressive treatment; a reduction of proteinuria below
Effects of treatments on pattern of proteinuria the nephrotic range was in fact hardly achieved. The
current work is the first study that addresses the questionIn basal conditions, all the patients showed a tubular
pattern of proteinuria at SDS-PAGE analysis; in particu- as whether enhancement of RAS suppression amelio-
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rates the antiproteinuric response in NPGN patients with (Fig. 2), despite the presence of a stepwise elevation in
PRA values. Of note, the results of the current studymoderate proteinuria and preserved renal function that
are usually treated with symptomatic therapy. Suppression actually differ from what has been reported in nondia-
betic glomerulopathies characterized by expansion ofof RAS was pushed up to the maximal degree by stepwise
increase of ramipril dosage from 2.5 up to 20 mg/day, mesangial area. Similarly to IgA nephropathy, in fact,
also in NPGN patients with nephrotic syndrome eitherthat is, a dose four-fold greater than the maximal dosage
of the REIN study [11], followed by add-on treatment the increase of the dose of ACE-I/ARA or the coadmin-
istration of the two agents allow a greater decrement ofwith 300 mg/day of irbesartan, that is, the maximal dose
used currently in clinical trials [25]. This two-phase analy- proteinuria [19–24]. On the basis of these findings, it
is reasonable to hypothesize that after enhancing RASsis is essential to verify the presence of additive effects of
the combination therapy since both agents act of the same suppression a larger antiproteinuric effect may become
manifest only in the presence of significant mesangialsystem. Indeed, Agarwal [26] has recently demonstrated
in diabetic patients with chronic renal failure the absence expansion secondary to mesangium overload, as in the
presence of severe proteinuria, or primarily caused byof any specific advantage of adding ARA on top of ACE-I
when the latter is administered at high dose. Conversely, the underlying disease, as in the case of IgA nephropa-
thy. Indeed, proliferation of mesangial cells is associatedin most of the studies published to date on the antipro-
teinuric effect of combined therapy in both proliferative with high sensitivity to the beneficial effects of ACE-I
and ARA on glomerular structure and function [30];and NPGN, the impact of ACE-I  ARA has been
tested without preliminary evaluation of the effects of on the other hand, the glomerular response to Ang II
disappears after mesangial cell lysis [31]. This hypothesisACE-I at doses higher than usual.
All the ramipril doses administered and the combina- may therefore account for the lack of a greater antipro-
teinuric effect in response to maximized RAS suppres-tion therapy were well tolerated and not associated with
significant side effects. Of note, however, hemoglobin lev- sion in our NPGN patients with moderate proteinuria.
In our patients, we had to maintain a normal salt intakeels tended to diminish when ramipril dose was increased,
with the maximal reduction of 0.8 g/dL on average, de- because of the optimal blood presssure levels detected
prior to the study; consequently, we cannot exclude thattected after administration of the 20 mg dose. On the
contrary, no hemoglobin change was noted after admin- a larger antiproteinuric effect of maximal RAS suppres-
sion would have been attained at low sodium diet [19, 23].istration of irbesartan alone. The class-specific lowering
effect of ACE-I on hemoglobin levels, recently reported Furthermore, this trial was designed to assess the short-
term antiproteinuric response to a stepwise enhancementalso in renal transplant recipients [27], has been ascribed
to the reduced degradation of a physiologic inhibitor of of RAS suppression; therefore, we cannot exclude that
the higher doses of ramipril or add-on ARA treatmenterythropoiesis [28]. The clinical implication of these data
may not be trivial because even a 0.5 g/dL decrement may allow a more favorable outcome of renal function
in the long-term. Nevertheless, the short-term antipro-of hemoglobin levels is associated with significant growth
of left ventricular mass in patients with anemia secondary teinuric response achieved by the low doses of ACE-I
or ARA can be reasonably considered as already pre-to chronic renal failure [29].
Ramipril induced a reduction of proteinuria, of about dictive of a more benign course [1, 9–11].
Our clinical study was not primarily designed to inves-30% on average (Fig. 2), in the absence of changes of
creatinine clearance and salt intake. The 2.5 mg/day dose tigate on the mechanism(s) of the antiproteinuric re-
sponse to RAS suppression; indeed, previous studies inof ramipril was sufficient to determine this effect, and a
similar reduction was observed after irbesartan alone. nondiabetic patients with nephrotic syndrome have ad-
dressed this issue, showing that either standard or higherRestoration of proteinuria to basal values in the washout
periods demonstrates that the positive results on protein- ACE-I doses induce a specific improvement of glomeru-
lar barrier size-selective dysfunction independently fromuria were not achieved by chance or dependent on spon-
taneous remission of underlying disease. The extent of the antihypertensive effect [20, 22, 32]. In the present
work, blood pressure decreased of about 10% after thethe antiproteinuric response to the usual doses of ACE-I
or ARA is analogous to that we have previously ob- 2.5 mg dose of ramipril, and, by the same extent, after ir-
besartan with no further decrement in response to higherserved in a small group of patients with similar character-
istics (moderate proteinuria, normal GFR, and blood ACE-I doses or to add-on ARA. Nevertheless, analysis
of covariance and the absence of any correlation betweenpressure) but with IgA nephropathy [12, 13].
However, at variance with our previous studies [12, 13], the changes of proteinuria and of blood pressure suggest
that the decrease of proteinuria was largely independentin the current work no improvement of the antiprotein-
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